September 2016

2

Neurostimulation Transformed

3

Urinary Incontinence – Underserved Patient Population

People in the UK suffer from Urinary Incontinence1 (over 200 Million people worldwide)

1. http://www.nhs.uk/conditions/Incontinence-urinary/Pages/Introduction.aspx (accessed 31/8/2016)2. Irwin DE, Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six

European countries. BJU Int. 2006 Jan;97(1):96-100.3. Turner DA et al, The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK.

BJU Int. 2004 Jun;93(9):1246-52.

3-6 Million Of patients with OAB and Incontinence suffer from

Depression240% Patient report: social anxiety, withdrawal from day to day activities

£536M

NHS cost to treat urinary incontinence (1999/2000 prices)3.

4

Sacral Nerve Stimulation: Effective, but Complex and Expensive

(source: MDT InterStim Clinical Summary)

Lifetime NHS cost of Sacral Nerve Stimulation1, not taking into account complications

£24,000

Of patients required surgical intervention due to adverse event

%15-42%

1. Assuming 2 device replacement over lifetime: £10482 per initial implant and £6700 for each replacement

5

BlueWind System – Minimally Invasive Neurostimulation

Small Passive Implant

External Control

Unit

Physician Programme

r

• The implant is a micro (0.3cc) neuro-stimulators placed at the desired treatment site, adjacent to the target nerve.

• The implant is then wirelessly powered and controlled by an external device

Closed loop RF energy

and data transfer

6

Clinical Improvement: UI Response36 patient study conducted in the UK and Belgium

BlueWind OAB clinical results are comparable

to competing neurostimulation

solutions, without the invasive pelvic

procedure

Baseline (n=29) Month 1 (n=28) Month 3 (n=29) Month 6 (n=29)0

1

2

3

4

5

6

7

86.7

3.9 4.1 3.93.1

2.1 2.1 2.2

1.8 1.4 1.2 1.1

Leaks/day

Pads change/day

Leaks severity

Per d

ay

7

Cost Drivers Simplified procedure, 30 min under local

Anesthesia Lower complication rate

1/36 required surgical intervention No batteries no replacement

procedures Treatment efficacy lower ongoing

treatment cost

8

Conclusion

A study investigator: “All patients were given the option of enrolling in this BlueWind study or receiving a Sacral neurostimulation device. 100% chose the BlueWind device.”

Sep 2016

Thank You